Application of genomics to drug design:: the example of the histamine H3 receptor

被引:16
作者
Schwartz, JC
Morisset, S
Rouleau, A
Tardivel-Lacombe, J
Gbahou, F
Ligneau, X
Héron, A
Sasse, A
Stark, H
Schunack, W
Ganellin, RC
Arrang, JM
机构
[1] INSERM, U109, Unite Neurobiol & Pharmacol Mol, Ctr Paul Broca, F-75014 Paris, France
[2] Lab Bioprojet, F-75002 Paris, France
[3] Fac Sci Pharmaceut & Biol Paris, Lab Physiol, F-75006 Paris, France
[4] Free Univ Berlin, Inst Pharm, D-14195 Berlin, Germany
[5] UCL, Dept Chem, London WC1 H0AJ, England
关键词
histaminergic systems; H(3) autoreceptor; constitutive activity; inverse agonists;
D O I
10.1016/S0924-977X(01)00121-3
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
The histamine H(3) receptor was characterized in the 1980s as an autoreceptor regulating histamine release in brain. Since then, selective drugs have been designed, many of them displaying a high potency in vivo, and used in many studies to delineate the implications of cerebral histaminergic systems in physiological functions such as arousal or cognitive functions. The recent cloning of the H(3) receptor, more than 15 years later, has allowed to start molecular studies that led to important findings for optimization of drug design. In agreement some ligands display distinct affinities for the recombinant rat and human H3 receptors, a difference that we assign to two amino acids in the third transmembrane domain. In addition, H(3) autoreceptors present in the brain display high constitutive activity including in vivo. As a consequence, inverse agonists enhance histamine neuron activity and constitute a novel potential therapeutic approach to schizophrenia and Alzheimer's disease. (C) 2001 Elsevier Science BY All rights reserved.
引用
收藏
页码:441 / 448
页数:8
相关论文
共 32 条
[1]   AUTO-INHIBITION OF BRAIN HISTAMINE-RELEASE MEDIATED BY A NOVEL CLASS (H-3) OF HISTAMINE-RECEPTOR [J].
ARRANG, JM ;
GARBARG, M ;
SCHWARTZ, JC .
NATURE, 1983, 302 (5911) :832-837
[2]   HIGHLY POTENT AND SELECTIVE LIGANDS FOR HISTAMINE RECEPTORS-H-3 [J].
ARRANG, JM ;
GARBARG, M ;
LANCELOT, JC ;
LECOMTE, JM ;
POLLARD, H ;
ROBBA, M ;
SCHUNACK, W ;
SCHWARTZ, JC .
NATURE, 1987, 327 (6118) :117-123
[3]   H-3-RECEPTORS CONTROL HISTAMINE-RELEASE IN HUMAN-BRAIN [J].
ARRANG, JM ;
DEVAUX, B ;
CHODKIEWICZ, JP ;
SCHWARTZ, JC .
JOURNAL OF NEUROCHEMISTRY, 1988, 51 (01) :105-108
[4]  
CHERIFI Y, 1992, J BIOL CHEM, V267, P25315
[5]   THIOPERAMIDE, THE SELECTIVE HISTAMINE-H-3 RECEPTOR ANTAGONIST, ATTENUATES STIMULANT-INDUCED LOCOMOTOR-ACTIVITY IN THE MOUSE [J].
CLAPHAM, J ;
KILPATRICK, GJ .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1994, 259 (02) :107-114
[6]   Sensitivity of histamine H-3 receptor agonist-stimulated [S-35]GTP gamma[S] binding to pertussis toxin [J].
Clark, EA ;
Hill, SJ .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1996, 296 (02) :223-225
[7]   DIFFERENTIAL EFFECT OF SODIUM-IONS AND GUANINE-NUCLEOTIDES ON THE BINDING OF THIOPERAMIDE AND CLOBENPROPIT TO HISTAMINE H-3 RECEPTORS IN RAT CEREBRAL CORTICAL MEMBRANES [J].
CLARK, EA ;
HILL, SJ .
BRITISH JOURNAL OF PHARMACOLOGY, 1995, 114 (02) :357-362
[8]  
COSTA T, 1992, MOL PHARMACOL, V41, P549
[9]  
Ganellin C R, 1995, J Pharm Belg, V50, P179
[10]   EFFECTS OF HISTAMINE-H-3-RECEPTOR LIGANDS ON VARIOUS BIOCHEMICAL INDEXES OF HISTAMINERGIC NEURON ACTIVITY IN RAT-BRAIN [J].
GARBARG, M ;
TUONG, MDT ;
GROS, C ;
SCHWARTZ, JC .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1989, 164 (01) :1-11